Valuation: Supergenics

Market Cap 2.91Cr 71.7L 64.31L 58.77L 53.65L 1.01Cr 67Cr 1.04Cr 7.08Cr 2.82Cr 36Cr 2.69Cr 2.63Cr 113.54Cr P/E 2024
-9.45x
P/E 2025 -8.61x
Enterprise Value 3.25Cr 80.06L 71.81L 65.63L 59.91L 1.13Cr 75Cr 1.16Cr 7.91Cr 3.15Cr 40Cr 3.01Cr 2.94Cr 126.78Cr EV / Sales 2024
13.9x
EV / Sales 2025 5.78x
Free-Float
41.6%
Yield 2024 *
-
Yield 2025 -
1 year 0.25
Extreme 0.25
0.25
3 years 0.15
Extreme 0.15
0.6
5 years 0.15
Extreme 0.15
0.6
10 years 0.15
Extreme 0.15
0.6
Manager TitleAgeSince
Chief Executive Officer 48 24/04/2019
Corporate Secretary - 02/06/2022
Director TitleAgeSince
Director/Board Member 48 24/04/2019
Director/Board Member 60 24/04/2019
Director/Board Member 46 28/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
+21.95%-.--%+21.95%+8.70% 71.7L
-4.83%+3.51%+53.62%+61.75% 6.59TCr
-1.34%+2.98%+24.79%+100.18% 5.65TCr
+0.02%+1.07%+10.63%+76.66% 5.69TCr
+5.09%+9.89%+22.45%+107.48% 4.65TCr
+2.62%+1.68%+28.91%+37.01% 4.48TCr
+8.24%+0.51%+213.26%+792.66% 4.16TCr
-1.86%+10.13%+26.82%+53.22% 3.53TCr
-2.97%-9.84%+88.86%+76.17% 3.33TCr
-2.18%+7.06%+36.06%-4.95% 2.49TCr
Average +2.47%+2.93%+52.74%+130.89% 4.06TCr
Weighted average by Cap. +0.21%+3.40%+53.12%+142.95%

Financials

2024 2025
Net sales 53.22L 13.11L 11.76L 10.75L 10L 18.48L 12Cr 19.06L 1.3Cr 51.65L 6.58Cr 49.21L 48.15L 21Cr 56.25L 13.86L 12.43L 11.36L 10.37L 19.54L 13Cr 20.15L 1.37Cr 54.59L 6.95Cr 52.01L 50.9L 22Cr
Net income -72.81L -17.94L -16.09L -14.7L -13.42L -25.28L -17Cr -26.08L -1.77Cr -70.66L -9Cr -67.32L -65.88L -28Cr -33.66L -8L -7L -7L -6L -11.69L -7.79Cr -12.06L -81.91L -32.66L -4.16Cr -31.12L -30.45L -13Cr
Net Debt 44.77L 11.03L 10L 9L 8L 15.55L 10Cr 16.04L 1.09Cr 43.45L 5.53Cr 41.4L 40.51L 17Cr 33.94L 8L 7L 7L 6L 11.79L 7.86Cr 12.16L 82.61L 32.94L 4.19Cr 31.38L 30.71L 13Cr
Projected Income Statement - Annual - Supergenics
Logo Supergenics
Supergenics Berhad is a Malaysia-based management and investment holding company. The Company operates through three segments: Integrated Turnkey Solutions, Biomedical, and Investment Holding. Its Integrated Turnkey Solutions segment is engaged in the provision of integrated turnkey solutions for the related development of cleanrooms and the provision of related maintenance services. Its Biomedical segment is engaged in the provision of administrative health care services, operating medical laboratories, and developing regenerative wellness products. The Company provides laboratory services, including storage and handling of stem cell samples. Its services include stem cells, mesenchymal stem cells (MSC), natural killer (NK) cells, exosomes, and MSC exosomes. Its subsidiaries include Supergenics Solution Sdn. Bhd., Supergenics Life Science Sdn. Bhd., Supergenics Therapeutic Sdn. Bhd., Supergenics Bio Agro Sdn. Bhd., Supergenics Stembank Sdn. Bhd., and Supergenics Global Sdn. Bhd.
Employees
-
  1. Stock Market
  2. Stocks
  3. 03033 Stock